| Literature DB >> 20830292 |
Sevtap Savas1, Laurent Briollais, Irada Ibrahim-zada, Hamdi Jarjanazi, Yun Hee Choi, Mireia Musquera, Neil Fleshner, Vasundara Venkateswaran, Hilmi Ozcelik.
Abstract
Epidemiological studies have suggested an association between selenium intake and protection from a variety of cancer. Considering this clinical importance of selenium, we aimed to identify the genes associated with resistance to selenium treatment. We have applied a previous methodology developed by our group, which is based on the genetic and pharmacological data publicly available for the NCI60 cancer cell line panel. In short, we have categorized the NCI60 cell lines as selenium resistant and sensitive based on their growth inhibition (GI50) data. Then, we have utilized the Affymetrix 125K SNP chip data available and carried out a genome-wide case-control association study for the selenium sensitive and resistant NCI60 cell lines. Our results showed statistically significant association of four SNPs in 5q33-34, 10q11.2, 10q22.3 and 14q13.1 with selenium resistance. These SNPs were located in introns of the genes encoding for a kinase-scaffolding protein (AKAP6), a membrane protein (SGCD), a channel protein (KCNMA1), and a protein kinase (PRKG1). The knock-down of KCNMA1 by siRNA showed increased sensitivity to selenium in both LNCaP and PC3 cell lines. Furthermore, SNP-SNP interaction (epistasis) analysis indicated the interactions of the SNPs in AKAP6 with SGCD as well as SNPs in AKAP6 with KCNMA1 with each other, assuming additive genetic model. These genes were also all involved in the Ca(2+) signaling, which has a direct role in induction of apoptosis and induction of apoptosis in tumor cells is consistent with the chemopreventive action of selenium. Once our findings are further validated, this knowledge can be translated into clinics where individuals who can benefit from the chemopreventive characteristics of the selenium supplementation will be easily identified using a simple DNA analysis.Entities:
Mesh:
Substances:
Year: 2010 PMID: 20830292 PMCID: PMC2935366 DOI: 10.1371/journal.pone.0012601
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Distribution of NCI60 cell lines with respect to their response to Selenium treatment.
NCI60 cell line panel selenium response phenotypes.
| Selenium Resistant Cell Lines | Selenium Sensitive Cell Lines | |
|
| 786O | A549ATCC |
|
| A498 | CAKI1 |
|
| ACHN | CCRFCEM |
|
| COLO205 | HCT116 |
|
| HOP62 | HL60 |
|
| HT29 | HOP92 |
|
| K562 | IGROV1 |
|
| KM12 | NCIH226 |
|
| LOXIMVI | NCIH23 |
|
| M14 | NCIH460 |
|
| MALME3M | OVCAR4 |
|
| MOLT4 | SF295 |
|
| NCIH322M | SF539 |
|
| NCIH522 | SNB75 |
|
| OVCAR3 | U251 |
|
| OVCAR5 | UO31 |
|
| OVCAR8 | |
|
| RPMI8226 | |
|
| SF268 | |
|
| SKMEL2 | |
|
| SKMEL28 | |
|
| SKMEL5 | |
|
| SKOV3 | |
|
| SN12C | |
|
| SNB19 | |
|
| SR | |
|
| SW620 | |
|
| TK10 | |
|
| UACC257 | |
|
| UACC62 |
Summary of the whole-genome case-control association study for the Selenium resistant and sensitive NCI60 cell line panel.
| SNP ID (Affymetrix) | SNP ID (dbSNP) | Chr. | All. | Minor Allele in NCI60 | mAF in Resistant Panel N = 30 | mAF in Sensitive Panel N = 16 | CHISQ | Unadjusted p value | OR | L95 | U95 | FDR_BH | BONF | Genic Location |
| 2292894 | rs32076 | 5q33 | A/G | G | 0.018 | 0.46 | 24.69 | 6.74E-07 | 0.02 | 0.003 | 0.19 | 0.02 | 0.02 | intron 7 of |
| 354475 | rs2619641 | 10q22 | A/C | A | 0.037 | 0.57 | 30.73 | 2.96E-08 | 0.03 | 0.006 | 0.14 | 0.0009 | 0.0009 | intron 1 of |
| 326494 | rs10508958 | 10q11 | G/T | G | 0.23 | 0.77 | 21.69 | 3.20E-06 | 0.09 | 0.03 | 0.27 | 0.05 | 0.1 | intron 4 of |
| 822011 | rs8013938 | 14q13 | G/T | G | 0.08 | 0.58 | 24.5 | 7.41E-07 | 0.06 | 0.02 | 0.21 | 0.014 | 0.014 | intron 1 of |
Chr: chromosome; All: alleles; CHISQ: X2; OR: odds ratio; L95: lower confidence interval; U95: upper confidence interval; FDR_BH: False discovery rate by Benjamini and Hochberg; BONF: Bonferroni method.
Figure 2KCNMA1 knock down in LNCaP and PC3 cell lines using siRNA methodology.
The percent reduction in response is plotted as a bar graft, the first bar in each set indicating the absence and the second bar representing the presence of selenium treatment of both cell lines. The siRNA experiments are done in triplicates and the average is taken. The (*) indicates the statistically significant (p<0.05) differences in response to selenium treatment.
qRT-PCR results for KCNMA1 knock down.
| Beta actin | KCNMA1 | Ratio KCNMA1/Beta actin | |||||
| CT | Gene Copy # | Average | CT | Gene Copy # | Average | ||
|
| 15.2 | 2255.1 | 2176.0 | 17.5 | 2691.8 | 2937.3 | 1.4 |
|
| 15.3 | 2096.8 | 17.3 | 3182.7 | |||
|
| 14.1 | 4546.9 | 4531.9 | 16.9 | 4154.5 | 4076.9 | 0.9 |
|
| 14.1 | 4516.9 | 17.0 | 3999.3 | |||
|
| 14.4 | 3607.1 | 3756.1 | 17.0 | 3909.0 | 4000.3 | 1.1 |
|
| 14.3 | 3905.1 | 17.0 | 4091.7 | |||
|
| 13.8 | 5508.5 | 5490.4 | 16.9 | 4154.5 | 4477.8 | 0.8 |
|
| 13.8 | 5472.2 | 16.8 | 4801.0 | |||
|
| 14.6 | 3331.8 | 3245.9 | 18.5 | 1316.0 | 1301.1 | 0.4 |
|
| 14.6 | 3160.1 | 18.5 | 1286.3 | |||
|
| 14.6 | 3266.3 | 3277.2 | 19.4 | 648.3 | 673.9 | 0.2 |
|
| 14.6 | 3288.0 | 19.3 | 699.6 | |||
|
| 14.5 | 3443.9 | 3450.1 | 18.0 | 1811.8 | 1811.8 | 0.5 |
|
| 14.6 | 3456.2 | 18.1 | 1819.9 | |||
|
| 14.1 | 4607.5 | 5265.9 | 18.3 | 1486.5 | 1144.4 | 0.2 |
|
| 13.7 | 5924.3 | 19.1 | 802.3 |
C: control, Sc: scram, SE: selenium.
Figure 3A schematic representation of relationships among the KCNMA1, SGCD, PRKG1, and AKAP6 proteins.